FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2762563025> ?p ?o ?g. }

• W2762563025 abstract "e13111 Background: Lung cancer diagnosis now involves routine use of biomarker testing to identify the driver mutations. We conducted a survey of 111 medical oncologists across India to understand the current pattern of EGFR mutation testing at their respective centres. Methods: Medical oncologists from 111 institutes across India were interviewed face to face using a structured questionnaire. They were divided into two groups - Group 1 with in-house EGFR testing and Group 2 who send samples to central/commercial labs. Answers of the two groups were analysed to see the prevailing patterns of EGFR mutation testing and differences between the groups if any. Results: In India, 95% of medical oncologists recommend testing for EGFR mutations in patients with adenocarcinoma histology. 40% would also recommend testing in squamous histology. 80% of medical oncologists request for biomarker testing at the time of primary biopsy. From the time of biopsy, the average time duration to get EGFR test results is 18 days. In centres with in-house testing (Group 1), results are available in 10 days. 96% of the medical oncologists from Group 1 centres request for factoring additional sample for biomarker testing compared to only 69% from Group 2. 69% of medical oncologists in Group 1 centres would prefer to wait for the test results before initiating treatment compared to 46% in Group 2. EGFR TKIs are used in 60% of patients with diagnosed EGFR mutation in the first line. For patients in whom chemotherapy is initiated while waiting for test results, 50% of medical oncologists prefer completing 4-6 cycles before switching to targeted therapy. At the time of progression, rebiopsy is possible in 25% of the patients. Rapid disease progression and poor PS were the two most common reasons given for the low rebiopsy rates. Conclusions: Application of molecular testing is ‎improving. Yield can be improved by training of multidisciplinary team involved in tumor biopsy. There is scope and need to reduce the turnaround time. This will reduce the current scenario of commencing chemotherapy while waiting for test results. Increasing application of liquid biopsy will help in initial diagnosis as well as at relapse, especially for patients with poor PS or difficult access to tumor site." @default.
• W2762563025 created "2017-10-20" @default.
• W2762563025 creator A5003412464 @default.
• W2762563025 creator A5004249388 @default.
• W2762563025 creator A5008132804 @default.
• W2762563025 creator A5016745365 @default.
• W2762563025 creator A5018757115 @default.
• W2762563025 creator A5031219890 @default.
• W2762563025 creator A5034756571 @default.
• W2762563025 creator A5048420557 @default.
• W2762563025 creator A5048884097 @default.
• W2762563025 creator A5052114605 @default.
• W2762563025 creator A5055742091 @default.
• W2762563025 creator A5059703821 @default.
• W2762563025 creator A5060460410 @default.
• W2762563025 creator A5060722923 @default.
• W2762563025 creator A5064035855 @default.
• W2762563025 creator A5065710121 @default.
• W2762563025 creator A5074022987 @default.
• W2762563025 creator A5078127151 @default.
• W2762563025 creator A5081550933 @default.
• W2762563025 creator A5084580988 @default.
• W2762563025 date "2017-05-20" @default.
• W2762563025 modified "2023-10-01" @default.
• W2762563025 title "EGFR testing scenario across 111 centres in India: A questionnaire-based survey." @default.
• W2762563025 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e13111" @default.
• W2762563025 hasPublicationYear "2017" @default.
• W2762563025 type Work @default.
• W2762563025 sameAs 2762563025 @default.
• W2762563025 citedByCount "1" @default.
• W2762563025 countsByYear W27625630252019 @default.
• W2762563025 crossrefType "journal-article" @default.
• W2762563025 hasAuthorship W2762563025A5003412464 @default.
• W2762563025 hasAuthorship W2762563025A5004249388 @default.
• W2762563025 hasAuthorship W2762563025A5008132804 @default.
• W2762563025 hasAuthorship W2762563025A5016745365 @default.
• W2762563025 hasAuthorship W2762563025A5018757115 @default.
• W2762563025 hasAuthorship W2762563025A5031219890 @default.
• W2762563025 hasAuthorship W2762563025A5034756571 @default.
• W2762563025 hasAuthorship W2762563025A5048420557 @default.
• W2762563025 hasAuthorship W2762563025A5048884097 @default.
• W2762563025 hasAuthorship W2762563025A5052114605 @default.
• W2762563025 hasAuthorship W2762563025A5055742091 @default.
• W2762563025 hasAuthorship W2762563025A5059703821 @default.
• W2762563025 hasAuthorship W2762563025A5060460410 @default.
• W2762563025 hasAuthorship W2762563025A5060722923 @default.
• W2762563025 hasAuthorship W2762563025A5064035855 @default.
• W2762563025 hasAuthorship W2762563025A5065710121 @default.
• W2762563025 hasAuthorship W2762563025A5074022987 @default.
• W2762563025 hasAuthorship W2762563025A5078127151 @default.
• W2762563025 hasAuthorship W2762563025A5081550933 @default.
• W2762563025 hasAuthorship W2762563025A5084580988 @default.
• W2762563025 hasConcept C121608353 @default.
• W2762563025 hasConcept C126322002 @default.
• W2762563025 hasConcept C142724271 @default.
• W2762563025 hasConcept C143998085 @default.
• W2762563025 hasConcept C185592680 @default.
• W2762563025 hasConcept C2775934546 @default.
• W2762563025 hasConcept C2776256026 @default.
• W2762563025 hasConcept C2781182431 @default.
• W2762563025 hasConcept C2781197716 @default.
• W2762563025 hasConcept C55493867 @default.
• W2762563025 hasConcept C57742111 @default.
• W2762563025 hasConcept C71924100 @default.
• W2762563025 hasConceptScore W2762563025C121608353 @default.
• W2762563025 hasConceptScore W2762563025C126322002 @default.
• W2762563025 hasConceptScore W2762563025C142724271 @default.
• W2762563025 hasConceptScore W2762563025C143998085 @default.
• W2762563025 hasConceptScore W2762563025C185592680 @default.
• W2762563025 hasConceptScore W2762563025C2775934546 @default.
• W2762563025 hasConceptScore W2762563025C2776256026 @default.
• W2762563025 hasConceptScore W2762563025C2781182431 @default.
• W2762563025 hasConceptScore W2762563025C2781197716 @default.
• W2762563025 hasConceptScore W2762563025C55493867 @default.
• W2762563025 hasConceptScore W2762563025C57742111 @default.
• W2762563025 hasConceptScore W2762563025C71924100 @default.
• W2762563025 hasLocation W27625630251 @default.
• W2762563025 hasOpenAccess W2762563025 @default.
• W2762563025 hasPrimaryLocation W27625630251 @default.
• W2762563025 hasRelatedWork W1995185595 @default.
• W2762563025 hasRelatedWork W2004653124 @default.
• W2762563025 hasRelatedWork W2156551446 @default.
• W2762563025 hasRelatedWork W2263558526 @default.
• W2762563025 hasRelatedWork W2338890970 @default.
• W2762563025 hasRelatedWork W2401309814 @default.
• W2762563025 hasRelatedWork W2417708517 @default.
• W2762563025 hasRelatedWork W2566374614 @default.
• W2762563025 hasRelatedWork W2599823823 @default.
• W2762563025 hasRelatedWork W2605654091 @default.
• W2762563025 hasRelatedWork W2768135593 @default.
• W2762563025 hasRelatedWork W2974739562 @default.
• W2762563025 hasRelatedWork W2982541140 @default.
• W2762563025 hasRelatedWork W3021445693 @default.
• W2762563025 hasRelatedWork W3026840464 @default.
• W2762563025 hasRelatedWork W3081668514 @default.
• W2762563025 hasRelatedWork W3112223936 @default.
• W2762563025 hasRelatedWork W3171334578 @default.
• W2762563025 hasRelatedWork W3171757638 @default.
• W2762563025 hasRelatedWork W3199784514 @default.
• W2762563025 isParatext "false" @default.

• next